Share Name Share Symbol Market Type Share ISIN Share Description
Venn Life Sciences Holdings Plc LSE:VENN London Ordinary Share GB00B9275X97 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 6.85p 6.70p 7.00p - - - 0 01:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 12.5 -4.5 -6.6 - 5

AIM Schedule One - Ven Life Sciences Holdings plc

14/06/2019 11:00am

UK Regulatory (RNS & others)


TIDMVENN

RNS Number : 3315C

AIM

14 June 2019

 
        ANNOUNCEMENT TO BE MADE BY THE AIM APPLICANT PRIOR TO ADMISSION 
         IN ACCORDANCE WITH RULE 2 OF THE AIM RULES FOR COMPANIES ("AIM 
                                     RULES") 
 
 COMPANY NAME: 
 
   Venn Life Sciences Holdings plc 
 COMPANY REGISTERED OFFICE ADDRESS AND IF DIFFERENT, COMPANY 
  TRADING ADDRESS (INCLUDING POSTCODES) : 
 
   Registered Office: 
 
   PO Box W1J 6BD, Berkley Square House, 2(nd) Floor, Mayfair, 
   London, W1J 8DJ 
 
   Trading Office: 
 
   19 Railway Road, Dalkey, Dublin, Ireland 
 COUNTRY OF INCORPORATION: 
 
   England and Wales 
 COMPANY WEBSITE ADDRESS CONTAINING ALL INFORMATION REQUIRED 
  BY AIM RULE 26: 
 
   www.vennlifesciences.com/ and with effect from Admission, www.openorphan.com 
 COMPANY BUSINESS (INCLUDING MAIN COUNTRY OF OPERATION) OR, 
  IN THE CASE OF AN INVESTING COMPANY, DETAILS OF ITS INVESTING 
  POLICY). IF THE ADMISSION IS SOUGHT AS A RESULT OF A REVERSE 
  TAKE-OVER UNDER RULE 14, THIS SHOULD BE STATED: 
 
   This is a reverse takeover under Rule 14. 
 
   Open Orphan is Clinical Research Organisation that specialises 
   in rare and orphan drugs. The headquarters are in Dublin, Ireland 
   and the company also has offices in France, the Netherlands 
   and Germany. 
 DETAILS OF SECURITIES TO BE ADMITTED INCLUDING ANY RESTRICTIONS 
  AS TO TRANSFER OF THE SECURITIES (i.e. where known, number 
  and type of shares, nominal value and issue price to which 
  it seeks admission and the number and type to be held as treasury 
  shares): 
 
   Number of ordinary shares of 0.1 pence each in nominal value 
   ("Ordinary Shares") for which Admission will be sought: 253,493,259 
 
   Placing price per Ordinary Share: 5.6 pence 
 
   The are no restrictions as to the transferability of the Ordinary 
   Shares and no Ordinary Shares will be held in treasury. 
 CAPITAL TO BE RAISED ON ADMISSION (AND/OR SECONDARY OFFERING) 
  AND ANTICIPATED MARKET CAPITALISATION ON ADMISSION: 
 
   Capital to be raised on admission: GBP4.5 million 
 
   Anticipated market capitalisation on admission: GBP14.1 million 
 PERCENTAGE OF AIM SECURITIES NOT IN PUBLIC HANDS AT ADMISSION: 
 
   31.1% 
 DETAILS OF ANY OTHER EXCHANGE OR TRADING PLATFORM TO WHICH 
  THE AIM SECURITIES (OR OTHER SECURITIES OF THE COMPANY) ARE 
  OR WILL BE ADMITTED OR TRADED: 
 
   Euronext Growth 
 FULL NAMES AND FUNCTIONS OF DIRECTORS AND PROPOSED DIRECTORS 
  (underlining the first name by which each is known or including 
  any other name by which each is known): 
 
   Directors: 
 
   Brendan Buckley, Non-executive Chairman 
   Cathal Friel, Chief Executive Officer 
   Christian Milla, Chief Operating Officer 
   Tony Richardson, Corporate Development Officer 
   Michael Ryan, Senior non-executive Director 
 
   Proposed Director: 
 
   Maurice Treacy, Executive Director 
 FULL NAMES AND HOLDINGS OF SIGNIFICANT SHAREHOLDERS EXPRESSED 
  AS A PERCENTAGE OF THE ISSUED SHARE CAPITAL, BEFORE AND AFTER 
  ADMISSION (underlining the first name by which each is known 
  or including any other name by which each is known): 
 
   Before Admission 
    Name                   Number of Ordinary   Percentage of issued 
                                       Shares          share capital 
    Livingbridge VC LLP            13,081,337                  18.3% 
                          -------------------  --------------------- 
    Kees Groen                      4,780,320                   6.7% 
                          -------------------  --------------------- 
    Calculus                        4,696,461                   6.6% 
                          -------------------  --------------------- 
 
 
   After Admission 
    Name                      Number of Ordinary   Percentage of issued 
                                          Shares          share capital 
    Cathal Friel                      41,046,981                  16.2% 
                             -------------------  --------------------- 
    Tony Richardson                   16,313,388                   6.4% 
                             -------------------  --------------------- 
    Livingbridge VC LLP               13,081,337                   5.2% 
                             -------------------  --------------------- 
    Miton Asset Management             8,928,571                   3.5% 
                             -------------------  --------------------- 
    Crux Asset Management              8,928,571                   3.5% 
                             -------------------  --------------------- 
    Brendan Buckley                    7.845,860                   3.1% 
                             -------------------  --------------------- 
 NAMES OF ALL PERSONS TO BE DISCLOSED IN ACCORDANCE WITH SCHEDULE 
  2, PARAGRAPH (H) OF THE AIM RULES: 
 
   n/a 
 (i) ANTICIPATED ACCOUNTING REFERENCE DATE 
  (ii) DATE TO WHICH THE MAIN FINANCIAL INFORMATION IN THE ADMISSION 
  DOCUMENT HAS BEEN PREPARED (this may be represented by unaudited 
  interim financial information) 
  (iii) DATES BY WHICH IT MUST PUBLISH ITS FIRST THREE REPORTS 
  PURSUANT TO AIM RULES 18 AND 19: 
 
        (i) 31 December 
        (ii) 31 December 2018 
        (iii) 30 June 2019 due 30 September 2019, 31 December 2019 
        due 30 June 2020, 30 June 2020 due September 2020 
 EXPECTED ADMISSION DATE: 
 
   28 June 2019 
 NAME AND ADDRESS OF NOMINATED ADVISER: 
 
   Arden Partners plc 
   125 Old Broad Street 
   London 
   EC2N 1AR 
 NAME AND ADDRESS OF BROKER: 
 
   Arden Partners plc 
   125 Old Broad Street 
   London 
   EC2N 1AR 
 OTHER THAN IN THE CASE OF A QUOTED APPLICANT, DETAILS OF WHERE 
  (POSTAL OR INTERNET ADDRESS) THE ADMISSION DOCUMENT WILL BE 
  AVAILABLE FROM, WITH A STATEMENT THAT THIS WILL CONTAIN FULL 
  DETAILS ABOUT THE APPLICANT AND THE ADMISSION OF ITS SECURITIES: 
 A copy of the admission document containing full details about 
  the applicant and the admission of its securities will be available 
  on the Company's website, www.vennlifesciences.com 
 THE CORPORATE GOVERNANCE CODE THE APPLICANT HAS DECIDED TO 
  APPLY 
 
   The QCA Corporate Governance Code 2018 published by the Quoted 
   Companies Alliance 
 DATE OF NOTIFICATION: 
 
   14 June 2019 
 NEW/ UPDATE: 
 
   New 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

PAAGGUGWQUPBUBC

(END) Dow Jones Newswires

June 14, 2019 06:00 ET (10:00 GMT)

1 Year Venn Life Sciences Chart

1 Year Venn Life Sciences Chart

1 Month Venn Life Sciences Chart

1 Month Venn Life Sciences Chart
Your Recent History
LSE
VENN
Venn Life ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20190722 21:07:06